Watson earned a bachelor's degree in English from the University of Kentucky in 1949, and after a career in education, joined ORAU in 1959 as a record clerk in purchasing. In 2000, Watson received the Marshall Brucer Award for Distinguished Service to the Nuclear Medicine Community, the highest award given by SNM's Southeastern Chapter. In 1994, Watson was the first recipient of the Lifetime Scientific Achievement Award from the East Tennessee Chapter of the Association for Women in Science. She also received a Lifetime Achievement Award from
the East Tennessee Chapter of the Health Physics Society in 1993.
John L. Joyal Accepts Berson-Yalow Award for Abstract that Contributes Significantly to Basic/Clinical Radioassay

Ad Statistics
Times Displayed: 109208
Times Visited: 6638 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The authors of "Molecular Targeting of Prostate Cancer With Small Molecule Inhibitors of Prostate Specific Membrane Antigen (PSMA)" were awarded the Berson-Yalow Award. SNM's Scientific Program Committee funds this award, which is presented to the investigators who have submitted the most original scientific abstracts and made the most significant contribution to basic or clinical radioassay.
John L. Joyal, who has been director of biology at Molecular Insight Pharmaceuticals Inc., Cambridge, Mass., since 2005, accepted the award during the Radiopharmaceutical Sciences Council business meeting. Joyal has more than 20 years of oncology basic research and drug discovery experience with expertise in cell and molecular biology particularly in the areas of receptor biology, signal transduction pathways and in vitro assay development. Prior to joining Molecular Insight, he was director of discovery research at Phylogix Pharmaceuticals, Waltham, Mass., where he led a team evaluating the biology and mechanism of action of protein therapeutics for oncology supportive care.
Abstract co-authors include K.P. Maresca, S.M. Hillier, F.J. Femia, C. Barone, C.N. Zimmerman, J.A. Barrett, W.C. Eckelman and J. W. Babich, all with Molecular Insight Pharmaceuticals, Cambridge, Mass., and C.A. Foss and M.G. Pomper, both with the Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Md.
Back to HCB News